P/B
—
Cartesian Therapeutics
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. The company leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function.
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. The company leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function.
$205.7M
Market Cap • 10/7/2026
2007
(19 years)
Founded
2016
(10 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
139,3
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
—
EPS
—
Market Cap
Market Cap
205,7M
EV
121,9M
EV/Revenue
82,6
EV/EBITDA
-0,8
EV/EBIT
-0,8
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-9,7%
Total Yield
-9,7%
Payout
0%
Retained Earnings
-845,8M
Profitability
Gross Margin
100%
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
4630%
Capex/Revenue
141%
Capex/D&A
79,9%
Capex/OCF
-2,7%
SBC/OCF
—
% PPE
5,2%
% Goodwill
15,1%
ROE
—
ROIC
—
Growth
CAGR Op. Income 5Y
40,5%
CAGR Net Income 5Y
27,4%
CAGR EPS 5Y
-15,1%
Leverage
N.D./EBITDA
0,5
Debt/Equity
0%
Current Ratio
7,5
Quick Ratio
7,2
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!